Carmell Therapeutics Closes Series A
Carmell Therapeutics, a company developing blood plasma-based biomaterials that accelerate the repair of injured tissues, has raised an undisclosed amount of Series A financing. Harbor Light Capital Partners led the round, which included participation from Newlin Investment Company, the PLSG Accelerator Fund, Innovation Works, Ariel Savannah Angels, Blue Tree Allied Angels, and un-named individual investors. The money will help establish a pilot manufacturing facility and collect data for early clinical validation for Carmell’s first products.
15 April 2011•3 mins read
